MYGN Q3 2021 Earnings — Myriad Genetics, Inc. Revenue & Financial Results | Market Cap Arena

MYGNMyriad Genetics, Inc.

$454M

Q3 2021 Earnings

Healthcare Medical - Diagnostics & Research

Income Statement

Revenue

$167M+15.2% YoY

Gross Profit

$120M71.4% margin

Operating Income

-$80M-47.8% margin

Net Income

$25M14.7% margin

EPS (Diluted)

$0.30

QoQ Revenue Growth

-11.7%

Cash Flow

Operating Cash Flow

-$39M

Free Cash Flow

-$42M

Stock-Based Comp.

$10M

Balance Sheet

Total Assets

$1.3B

Total Liabilities

$367M

Stockholders' Equity

$969M

Cash & Equivalents

$295M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$167M	$145M	+15.2%
Gross Profit	$120M	$101M	+18.3%
Operating Income	-$80M	-$40M	-101.8%
Net Income	$25M	-$15M	+261.8%

Revenue Segments

Molecular Diagnostic Testing

$167M100%

Geographic Segments

UNITED STATES

$145M86%

Non-US

$23M14%